390 related articles for article (PubMed ID: 11929752)
1. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
[TBL] [Abstract][Full Text] [Related]
2. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
[TBL] [Abstract][Full Text] [Related]
3. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD
Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684
[TBL] [Abstract][Full Text] [Related]
4. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
[TBL] [Abstract][Full Text] [Related]
5. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.
Wang L; Calcedo R; Nichols TC; Bellinger DA; Dillow A; Verma IM; Wilson JM
Blood; 2005 Apr; 105(8):3079-86. PubMed ID: 15637142
[TBL] [Abstract][Full Text] [Related]
6. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
[TBL] [Abstract][Full Text] [Related]
7. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector.
Brunetti-Pierri N; Nichols TC; McCorquodale S; Merricks E; Palmer DJ; Beaudet AL; Ng P
Hum Gene Ther; 2005 Jul; 16(7):811-20. PubMed ID: 16000063
[TBL] [Abstract][Full Text] [Related]
8. Persistent expression of canine factor IX in hemophilia B canines.
Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
[TBL] [Abstract][Full Text] [Related]
9. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.
Chao H; Monahan PE; Liu Y; Samulski RJ; Walsh CE
Mol Ther; 2001 Sep; 4(3):217-22. PubMed ID: 11545612
[TBL] [Abstract][Full Text] [Related]
10. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.
Ehrhardt A; Xu H; Dillow AM; Bellinger DA; Nichols TC; Kay MA
Blood; 2003 Oct; 102(7):2403-11. PubMed ID: 12805062
[TBL] [Abstract][Full Text] [Related]
11. New and improved AAVenues: current status of hemophilia B gene therapy.
Brimble MA; Reiss UM; Nathwani AC; Davidoff AM
Expert Opin Biol Ther; 2016; 16(1):79-92. PubMed ID: 26524468
[TBL] [Abstract][Full Text] [Related]
12. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
[TBL] [Abstract][Full Text] [Related]
13. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
[TBL] [Abstract][Full Text] [Related]
14. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
[TBL] [Abstract][Full Text] [Related]
15. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
[TBL] [Abstract][Full Text] [Related]
17. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.
Herzog RW; Yang EY; Couto LB; Hagstrom JN; Elwell D; Fields PA; Burton M; Bellinger DA; Read MS; Brinkhous KM; Podsakoff GM; Nichols TC; Kurtzman GJ; High KA
Nat Med; 1999 Jan; 5(1):56-63. PubMed ID: 9883840
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression.
Fang B; Eisensmith RC; Wang H; Kay MA; Cross RE; Landen CN; Gordon G; Bellinger DA; Read MS; Hu PC
Hum Gene Ther; 1995 Aug; 6(8):1039-44. PubMed ID: 7578416
[TBL] [Abstract][Full Text] [Related]
19. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
[TBL] [Abstract][Full Text] [Related]
20. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.
Kay MA; Rothenberg S; Landen CN; Bellinger DA; Leland F; Toman C; Finegold M; Thompson AR; Read MS; Brinkhous KM
Science; 1993 Oct; 262(5130):117-9. PubMed ID: 8211118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
